Bispecific Domain Antibodies Targeting Serum Albumin And GLP-1 Or PYY
OwnerSteve Holmes, Lucy J. Holt +2inventors
InventorsSteve Holmes, Lucy J. Holt, Laurent S. Jespers, Ian M. Tomlinson
Life of this patent
Estimating the term…
Abstract
Drug fusions and conjugates that contain an incretin therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.
Claims73
A drug fusion having the formula:
- a-(X)n1-b-(Y)n2-c-(Z)n3-d or a-(Z)n3-b-(Y)n2-c-(X)n1-d,
- wherein
- X is an insulintropic agent or an analogue thereof;
- Y is an immunoglobulin heavy chain variable domain (VH) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (VL) that has binding specificity for serum albumin;
- Z is a polypeptide drug that has binding specificity for a target;
- a, b, c and d are independently a polypeptide comprising one to about 100 amino acid residues or absent;
- n1 is one to about 10;
- n2 is one to about 10;
- and
- n3 is zero to about 10.
A drug fusion comprising moieties X′ and Y′, wherein X′ is GLP-I or an analogue thereof;
- and Y′ is an immunoglobulin heavy chain variable domain (VH) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (VL) that has binding specificity for serum albumin.
A drug conjugate comprising an immunoglobulin heavy chain variable domain (VH) that has binding specificity for serum albumin, or an immunoglobulin light chain variable domain (VL) that has binding specificity for serum albumin;
- and GLP-1 or an analogue thereof that is covalently bonded to said VH or VL.
A drug conjugate or fusion comprising an insulinotropic agent and an antibody fragment that binds an antigen, wherein the antigen acts to increase the half-life of the drug conjugate or fusion in vivo.
(canceled)
A drug comprising GLP-1 or an analogue thereof and a protein moiety comprising an antigen binding site, wherein the antigen binding site binds an antigen which acts to increase the half-life of the drug conjugate in vivo, with the proviso that the protein moiety is not a peptide having 10-30 amino acids.
A drug fusion comprising GLP-1 or an analogue thereof and a protein moiety comprising an antigen binding site, wherein the antigen binding site binds an antigen which acts to increase the half-life of the drug conjugate in vivo.
(canceled)
(canceled)
59-61. (canceled)
Dependencies are inferred from the claim text.